Taylor Financial Group Inc. Sells 716 Shares of Pfizer Inc. (NYSE:PFE)

Taylor Financial Group Inc. reduced its position in Pfizer Inc. (NYSE:PFE) by 5.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,991 shares of the biopharmaceutical company’s stock after selling 716 shares during the quarter. Taylor Financial Group Inc.’s holdings in Pfizer were worth $345,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer in the 4th quarter valued at about $26,000. Rialto Wealth Management LLC bought a new position in Pfizer in the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the 4th quarter valued at about $28,000. Noble Wealth Management PBC acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $31,000. Finally, Curio Wealth LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $32,000. 68.36% of the stock is owned by institutional investors.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on PFE shares. Citigroup reduced their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Bank of America reiterated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Performance

NYSE:PFE opened at $26.07 on Tuesday. The company has a fifty day moving average of $26.22 and a 200-day moving average of $27.10. The firm has a market capitalization of $147.72 billion, a P/E ratio of 18.49, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.10 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.